WO2025002299 - COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF COMPLEMENT FACTOR B (CFB)
National phase entry:
Publication Number
WO/2025/002299
Publication Date
02.01.2025
International Application No.
PCT/CN2024/102170
International Filing Date
28.06.2024
Title **
[English]
COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF COMPLEMENT FACTOR B (CFB)
[French]
COMPOSITIONS ET PROCÉDÉS POUR INHIBER L'EXPRESSION DU FACTEUR B DU COMPLÉMENT (CFB)
Applicants **
SHANGHAI ARGO BIOPHARMACEUTICAL CO., LTD.
Inventors
SHU, Dongxu
SHAO, Pengcheng Patrick
XIA, Shiwei
Priority Data
PCT/CN2023/103142
28.06.2023
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4329 | |
| EPO | Filing, Examination, Granting | 67299 | |
| Japan | Filing, Examination, Granting | 4100 | |
| South Korea | Filing, Examination, Granting | 6105 | |
| USA | Filing, Examination, Granting | 19590 |
Total:
101,423
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Compositions and methods useful to reduce expression of CFB gene and for treatment of CFB-associated diseases and conditions are provided. Provided are CFB dsRNA agents, CFB antisense polynucleotide agents, compositions comprising CFB dsRNA agents, and compositions comprising CFB antisense polynucleotide agents that can be used to reduce CFB expression in cells and subjects.[French]
L'invention concerne des compositions et des procédés utiles pour réduire l'expression du gène CFB et pour le traitement de maladies et d'états associés à CFB. L'invention concerne des agents ARNdb du CFB, des agents polynucléotidiques antisens du CFB, des compositions comprenant des agents ARNdb du CFB, et des compositions comprenant des agents polynucléotidiques antisens du CFB qui peuvent être utilisés pour réduire l'expression de CFB chez des cellules et des sujets.